Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial

Ira M. Jacobson, Robert S. Brown, Bradley Freilich, Nezam Afdhal, Paul Y. Kwo, John Santoro, Scott Becker, Adil E. Wakil, David Pound, Eliot Godofsky, Robert Strauss, David Bernstein, Steven Flamm, Mary Pat Pauly, Pabak Mukhopadhyay, Louis H. Griffel, Clifford A. Brass – 25 September 2007 – This prospective, multicenter, community‐based and academic‐based, open‐label, investigator‐initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG‐IFN) alfa‐2b plus a flat or weight‐based dose of ribavirin (RBV) in adults with chronic hepatitis C.

Bone disorders in chronic liver disease

Jane Collier – 20 September 2007 – Osteomalacia rarely occurs in adult patients with chronic liver disease despite a low serum vitamin D level being reported in up to two‐thirds of patients with cirrhosis. In contrast, osteoporosis, which increases the risk of vertebral fractures, occurs in 12%‐55% of patients with cirrhosis. Although the prevalence is probably falling, as shown by a fall from 57%‐26% in patients with biliary disease requiring liver transplantation over the last 2 decades, it still accounts for significant patient morbidity.

Subscribe to